{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:17Z","timestamp":1794047357331,"version":"4.8.0"},"reference-count":21,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2020.254235","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T12:22:01Z","timestamp":1589545321000},"page":"875-880","source":"Crossref","is-referenced-by-count":26,"title":["Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial"],"prefix":"10.3324","volume":"106","author":[{"family":"Sandra Maria Dold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Mandy-Deborah M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Gabriele Ihorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Christian Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Wolfram P\u00f6nisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Lars-Olof M\u00fcgge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Stefan Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Johannes Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Christine Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ralph W\u00e4sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Monika Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,5,15]]},"reference":[{"key":"22827","unstructured":"Kumar S, Paiva B, Anderson KC. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346."},{"key":"22828","doi-asserted-by":"crossref","unstructured":"Palumbo A, Bringhen S, Ludwig H. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011; 118(17):4519-4529.","DOI":"10.1182\/blood-2011-06-358812"},{"key":"22829","doi-asserted-by":"crossref","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-383.","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"22830","doi-asserted-by":"crossref","unstructured":"Kleber M, Ihorst G, Gross B. Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. Clin Lymphoma Myeloma Leuk. 2013; 13(5):541-551.","DOI":"10.1016\/j.clml.2013.03.013"},{"key":"22831","doi-asserted-by":"crossref","unstructured":"Larocca A, Dold SM, Zweegman S. Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia. 2018; 32(8):1697-1712.","DOI":"10.1038\/s41375-018-0142-9"},{"key":"22832","doi-asserted-by":"crossref","unstructured":"Engelhardt M, Ihorst G, Duque-Afonso J. Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age. Haematologica. 2020; 105(5):1183-1188.","DOI":"10.3324\/haematol.2019.242958"},{"key":"22833","doi-asserted-by":"crossref","unstructured":"Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004; 291(22):2720-2726.","DOI":"10.1001\/jama.291.22.2720"},{"key":"22834","doi-asserted-by":"crossref","unstructured":"Mateos M-V, Dimopoulos MA, Cavo M. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018; 378(6):518-528.","DOI":"10.1056\/NEJMoa1714678"},{"key":"22835","doi-asserted-by":"crossref","unstructured":"Facon T, Kumar S, Plesner T. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N engl J Med. 2019; 380(22):2104-2115.","DOI":"10.1056\/NEJMoa1817249"},{"key":"22836","doi-asserted-by":"crossref","unstructured":"Ruiz M, Reske T, Cefalu C, Estrada J.. Management of elderly and frail elderly cancer patients: the importance of comprehensive geriatrics assessment and the need for guidelines. Am J Med Sci. 2013; 346(1):66-69.","DOI":"10.1097\/MAJ.0b013e31826d59aa"},{"key":"22837","doi-asserted-by":"crossref","unstructured":"Palumbo A, Bringhen S, Mateos M-V. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015; 125(13):2068-2074.","DOI":"10.1182\/blood-2014-12-615187"},{"key":"22838","doi-asserted-by":"crossref","unstructured":"Engelhardt M, Dold SM, Ihorst G. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica. 2016; 101(9):1110-1119.","DOI":"10.3324\/haematol.2016.148189"},{"key":"22839","doi-asserted-by":"crossref","unstructured":"Engelhardt M, Domm A-S, Dold SM. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017; 102(5):910-921.","DOI":"10.3324\/haematol.2016.162693"},{"key":"22840","doi-asserted-by":"crossref","unstructured":"Kleber M, Ihorst G, Terhorst M. Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM\u2013comorbidity score. Blood. Cancer J. 2011; 1(9):e35.","DOI":"10.1038\/bcj.2011.34"},{"key":"22841","doi-asserted-by":"crossref","unstructured":"Kleber M, Ihorst G, Udi J, Koch B, W\u00e4sch R, Engelhardt M.. Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal. Clin Lymphoma Myeloma Leuk. 2012; 12(1):38-48.","DOI":"10.1016\/j.clml.2011.09.216"},{"key":"22842","doi-asserted-by":"crossref","unstructured":"Mellqvist U-H. New prognostic tools for myeloma. Blood. 2015; 125(13):2014-2015.","DOI":"10.1182\/blood-2015-02-626408"},{"key":"22843","doi-asserted-by":"crossref","unstructured":"Fried LP, Tangen CM, Walston J. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001; 56(3):M146-156.","DOI":"10.1093\/gerona\/56.3.M146"},{"key":"22844","doi-asserted-by":"crossref","unstructured":"Greil C, Engelhardt M, Ihorst G. Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life. Haematologica. 2019; 104(2):370-379.","DOI":"10.3324\/haematol.2018.200881"},{"key":"22845","doi-asserted-by":"crossref","unstructured":"Waldschmidt JM, Keller A, Ihorst G. Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I\/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma). Haematologica. 2018; 103(10):e473-e479.","DOI":"10.3324\/haematol.2018.189969"},{"key":"22846","doi-asserted-by":"crossref","unstructured":"Larocca A, Palumbo A.. How I treat fragile myeloma patients. Blood. 2015; 126(19):2179-2185.","DOI":"10.1182\/blood-2015-05-612960"},{"key":"22847","doi-asserted-by":"crossref","unstructured":"Zweegman S, Engelhardt M, Larocca A. EHA SWG on \u2018Aging and Hematology.\u2019 Elderly patients with multiple myeloma: towards a frailty approach?. Curr Opin Oncol. 2017; 29(5):315-321.","DOI":"10.1097\/CCO.0000000000000395"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9750\/70871","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9750\/70872","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9750\/70871","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:57:07Z","timestamp":1794045427000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,15]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2020.254235","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,15]]}}}